However, since the research on various SH2 inhibitors is still in early stages and is mostly focussed on haematological malignancies, more investigations are required to validate their efficacy and safety for the treatment of other cancers dependent on STAT5 signalling both in vitro and in vivo. The gene discussed is STAT5B; the disease is cancer.